National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents

Journal of the American Academy of Dermatology

Volumn 59, Issue 2, 2008, Pages 209-217

  Doherty, Sean D ^a   Van Voorhees, Abby ^b   Lebwohl, Mark G ^c   Korman, Neil J ^d   Young, Melodie S ^e   Hsu, Sylvia ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BCG VACCINE; CALCIPOTRIOL; CYCLOSPORIN; DITHRANOL; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; ISONIAZID; METHOTREXATE; PYRAZINAMIDE; RIFAMPICIN; SALICYLIC ACID; STEROID; T LYMPHOCYTE RECEPTOR; TAR; TAZAROTENE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; BCG VACCINATION; CONSENSUS; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; LIVER TOXICITY; MONOTHERAPY; PATIENT COMPLIANCE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SCREENING; SCREENING TEST; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; DECISION TREES; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MASS SCREENING; RECEPTORS, TUMOR NECROSIS FACTOR; SOCIETIES, MEDICAL; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 47049122733     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.03.023     Document Type: Article

References (52)

1. Chaudhari U., Romano P., Mulcahy L.D., Dooley L.T., Baker D.G., and Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357 (2001) 1842-1847
2. Gottlieb A.B., Matheson R.T., Lowe N., Krueger G.G., Kang S., Goffe B.S., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139 (2003) 1627-1632
3. Saurat J.H., Stingl G., Dubertret L., Papp K., Langley R.G., Ortonne J.P., et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158 (2008) 558-566 Epub 2007 Nov 28
4. Menter A., Tyring S.K., Gordon K., Kimball A.B., Leonardi C.L., Langley R.G., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58 (2008) 106-115
5. Antoni C., Dechant C., Hanns-Martin Lorenz P.D., Wendler J., Ogilvie A., Lueftl M., et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47 (2002) 506-512
6. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
7. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 3279-3289
8. Graves J.E., Nunley K., and Heffernan M.P. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 56 (2007) e55-e79
9. Kaplan G., and Freedman V.H. The role of cytokines in the immune response to tuberculosis. Res Immunol 147 (1996) 565-572
10. American Thoracic Society, and CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161 (2000) S221-S247
11. Flynn J.L., and Chan J. Tuberculosis: latency and reactivation. Infect Immun 69 (2001) 4195-4201
12. Taylor Z., Nolan C.M., Blumberg H.M., American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 54 (2005) 1-81
13. Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol 49 (1991) 380-387
14. Kindler V., Sappino A.P., Grau G.E., Piguet P.F., and Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56 (1989) 731-740
15. Ellerin T., Rubin R.H., and Weinblatt M.E. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48 (2003) 3013-3022
16. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
17. Solomon D.H. The comparative safety and effectiveness of TNF-alpha antagonists [corrected] J Manag Care Pharm 2s007;13:S7-18. Erratum in 13 (2007) 292
18. Remicade (infliximab) for IV injection: prescribing information (2006), Centocor, Inc, Malvern (PA). http://www.fda.gov/cder/foi/label/2006/103772s5138lbl.pdf Accessed August 11, 2007
19. Humira (adalimumab) for subcutaneous injection: prescribing information. North Chicago (IL): Abbot Biotechnology. Available at: http://www.fda.gov/cder/foi/label/2002/adalabb123102LB.pdf Accessed August 11, 2007.
20. CDC. Guide for primary health care providers: targeted tuberculin testing and treatment of latent tuberculosis infection. Available at: www.cdc.gov/tb/pubs/LTBI/pdf/TargetedLTBI05.pdf. Accessed January 2, 2008.
21. Gardam M.A., Keystone E.C., Menzies R., Manners S., Skamene E., Long R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3 (2003) 148-155
22. Shekelle P.G., Woolf S.H., Eccles M., and Grimshaw J. Clinical guidelines: developing guidelines. BMJ 318 (1999) 593-596
23. Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR Morb Mortal Wkly Rep 53 (2004) 683-686
24. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 161 (2000) 1376-1395
25. Winthrop K.L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2 (2006) 602-610
26. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 6 (2005) 800-805
27. Winthrop K.L., Siegel J.N., Jereb J., Taylor Z., and Iademarco M.F. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 52 (2005) 2968-2974
28. Pai M., Riley L.W., and Colford Jr. J.M. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 4 (2004) 761-776
29. Sellam J., Hamdi H., Roy C., Baron G., Lemann M., Puéchal X., et al. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 66 (2007) 1610-1615
30. Mazurek G.H., Jereb J., Lobue P., Iademarco M.F., Metchock B., Vernon A., Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, and Centers for Disease Control and Prevention (CDC). Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54 (2005) 49-55
31. Hatemi G., Melikoglu M., Fresko I., Masatlioglu S., Tascilar K., and Yazici H. Infliximab does not suppress the tuberculin skin test (purified protein derivative). J Rheumatol 34 (2007) 474-480
32. Matulis G., Jüni P., Villiger P.M., and Gadola S.D. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a mycobacterium tuberculosis antigen specific IFN-gamma assay. Ann Rheum Dis 67 (2008) 84-90
33. Winthrop K.L. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}. Ann Rheum Dis 64 (2005) iv29-iv30
34. Centers for Disease Control and Prevention (CDC), and American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 52 (2003) 735-739
35. Priest D.H., Vossel Jr. L.F., Sherfy E.A., Hoy D.P., and Haley C.A. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clin Infect Dis 39 (2004) 1764-1771
36. Mariette X., and Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 62 (2003) 791
37. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., Montero D., Pascual-Gomez E., Mola E.M., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52 (2005) 1766-1772
38. Raychaudhuri S., Shmerling R., Ermann J., and Helfgott S. Development of active tuberculosis following initiation of infliximab despite appropriate prophylaxis. Rheumatology (Oxford) 46 (2007) 887-888
39. Gomez-Reino J.J., Carmona L., Angel Descalzo M., and Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57 (2007) 756-761
40. Parra Ruiz J., Ortego Centeno N., and Raya Alvarez E. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol 30 (2003) 1657-1658
41. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.Y., Shealy D., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301 (2002) 418-426
42. Enbrel (etanercept) for subcutaneous injection: prescribing information (2003), Immunex Corporation, Thousand Oaks (CA). http://www.fda.gov/cder/foi/label/2003/etanimm060503LB.pdf Accessed August 13, 2007
43. Wallis R.S., Broder M., Wong J., and Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39 (2004) 1254-1255
44. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52 (2005) 3403-3412
45. Smith J.D., and Knox J.M. Psoriasis, methotrexate and tuberculosis. Br J Dermatol 84 (1971) 590-593
46. di Girolamo C., Pappone N., Melillo E., Rengo C., Giuliano F., and Melillo G. Cavitary lung tuberculosis in a rheumatoid arthritis patient treated with low-dose methotrexate and steroid pulse therapy. Br J Rheumatol 37 (1998) 1136-1137
47. Binymin K., and Cooper R.G. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford) 40 (2001) 341-342
48. Vanhoof J., Landewe S., Van Wijngaerden E., and Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 62 (2003) 1241-1242
49. Mor A., Bingham III C.O., Kishimoto M., Izmirly P.M., Greenberg J., Reddy S., et al. Methotrexate combined with isoniazid therapy for latent tuberculosis is well tolerated in rheumatoid arthritis patients: experience from an urban arthritis clinic. Ann Rheum 67 (2008) 462-465 Epub 2007 Aug 20
50. Behnam S.M., Behnam S.E., and Koo J.Y. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol 4 (2005) 189-194
51. Vachharajani TJ, Oza UG, Phadke AG, Kirpalani AL. Tuberculosis in renal transplant recipients: rifampicin sparing treatment protocol. Int Urol Nephrol 2002-2003;34:551-3.
52. Lebwohl M., Bagel J., Gelfand J.M., Gladman D., Gordon K.B., Hsu S., et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 58 (2008) 94-105